Teva

News

Astellas pays $285m for Audax cancer drug, and other deals

Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.

News

White House signs pricing deals with nine more pharmas

Nine mid-sized pharmas have signed up for the Trump administration's Most-Favoured Nation (MFN) pricing deals, pledging almost $20bn in investments.

News

Teva makes its first M&A play in years, buying Emalex

Teva has made its first pipeline-building acquisition in almost a decade, buying Tourette syndrome drug developer Emalex for up to $900m.

News

Cheaper Soliris biosimilars reach the US market

The first biosimilars of AstraZeneca/Alexion's blockbuster complement C5 inhibitor Soliris have been launched in the US at a discount to the brand.

News

NHS England relaunches anti-smoking pill programme

A daily pill that helps people stop smoking is to be offered by the NHS in England once again after it was withdrawn from sale in 2021 due to quality issues.

News

Teva fined €462.6m for antitrust delay to MS drug rivals

The European Commission has delivered a hefty fine to Teva for abusing a dominant position in multiple sclerosis by artificially extending the patent protection for former blockbuster Copax

Teva

Editor's Picks